2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.0 - CI Build

2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by Centers for Disease Control and Prevention (CDC). This guide is not an authorized publication; it is the continuous build for version 2022.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/opioid-cds-r4/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 2022 CDC Clinical Practice Guideline - Profiles
... 3 2022 CDC Clinical Practice Guideline - Terminology
... 4 2022 CDC Clinical Practice Guideline - Examples
... 5 2022 CDC Clinical Practice Guideline - Documentation
.... 5.1 2022 CDC Clinical Practice Guideline - Implementation Documentation
.... 5.2 2022 CDC Clinical Practice Guideline - Integration Documentation
.... 5.3 2022 CDC Clinical Practice Guideline - Process Documentation
.... 5.4 2022 CDC Clinical Practice Guideline - Service Documentation
... 6 2022 CDC Clinical Practice Guideline - Downloads
... 7 2022 CDC Clinical Practice Guideline - Acute Pain
... 8 2022 CDC Clinical Practice Guideline - Quick Start
... 9 Chronic Pain Decision Documentation
... 10 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration
.... 10.1 OpioidCDS Recommendation 01 - CQL Source
... 11 Recommendation #2 - Opioid Therapy Goals Discussion
.... 11.1 OpioidCDS Recommendation 02 - CQL Source
... 12 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy
.... 12.1 OpioidCDS Recommendation 03 - CQL Source
... 13 Recommendations #4 and #5 - Lowest Effective Dose
.... 13.1 OpioidCDS Recommendations 04 and 05 - CQL Source
... 14 Recommendation #6 - Prescribe Lowest Effective Dose and Duration
.... 14.1 OpioidCDS Recommendation 06 - CQL Source
... 15 Recommendation #7 - Opioid Therapy Risk Assessment
.... 15.1 OpioidCDS Recommendation 07 - CQL Source
... 16 Recommendation #8 - Naloxone Consideration
.... 16.1 OpioidCDS Recommendation 08 - CQL Source
... 17 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions
.... 17.1 OpioidCDS Recommendation 09 - CQL Source
... 18 Recommendation #10 Order Sign Variation - Urine Drug Testing
.... 18.1 OpioidCDS Recommendation 10 Order Sign - CQL Source
... 19 Recommendation #10 Patient View Variation - Urine Drug Testing
.... 19.1 OpioidCDS Recommendation 10 Patient View - CQL Source
... 20 Recommendation #11 Order Select Variation - Concurrent Use of Opioids and Benzodiazepines
.... 20.1 OpioidCDS Recommendation 11 Order Select - CQL Source
... 21 Recommendation #11 Patient View Variation - Concurrent Use of Opioids and Benzodiazepines
.... 21.1 OpioidCDS Recommendation 11 Patient View - CQL Source
... 22 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder
.... 22.1 OpioidCDS Recommendation 12 (patient-view) - CQL Source
... 23 License and Legal Terms
... 24 Artifacts Summary
.... 24.1 HelloWorld
.... 24.2 HelloWorldPatientView
.... 24.3 CDCMMEClinicalConversionFactors
.... 24.4 OpioidCDSRoutines
.... 24.5 OpioidCDSCommon
.... 24.6 OpioidCDSCommonConfig
.... 24.7 OpioidLogicMK2020
.... 24.8 OpioidData2020
.... 24.9 FHIRHelpers
.... 24.10 FHIRModelInfo
.... 24.11 OpioidCDSREC10CommonLibrary
.... 24.12 OpioidCDSREC01Library
.... 24.13 OpioidCDSREC02Library
.... 24.14 OpioidCDSREC03Library
.... 24.15 OpioidCDSREC04And05Library
.... 24.16 OpioidCDSREC06Library
.... 24.17 OpioidCDSREC07Library
.... 24.18 OpioidCDSREC08Library
.... 24.19 OpioidCDSREC09Library
.... 24.20 OpioidCDSREC10OrderSignLibrary
.... 24.21 OpioidCDSREC10PatientViewLibrary
.... 24.22 OpioidCDSREC11OrderSelectLibrary
.... 24.23 OpioidCDSREC11PatientViewLibrary
.... 24.24 OpioidCDSREC12PatientViewLibrary
.... 24.25 OpioidRiskAssessmentActivityDefinition
.... 24.26 OpioidUrineScreeningActivityDefinition
.... 24.27
.... 24.28
.... 24.29 PlanDefinition - Hello World example to test CDS Service deployment
..... 24.29.1 Library
.... 24.30 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration
..... 24.30.1 Library
.... 24.31 Recommendation #2 - Opioid Therapy Goals Discussion
..... 24.31.1 Library
.... 24.32 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy
..... 24.32.1 Library
.... 24.33 Recommendations #4 and #5 - Lowest Effective Dose
..... 24.33.1 Library
.... 24.34 Recommendation #6 - Prescribe Lowest Effective Dose and Duration
..... 24.34.1 Library
.... 24.35 Recommendation #7 - Opioid Therapy Risk Assessment
..... 24.35.1 Library
.... 24.36 Recommendation #8 - Naloxone Consideration
..... 24.36.1 Library
.... 24.37 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions
..... 24.37.1 Library
.... 24.38 Recommendation #10 - Urine Drug Testing (order-select)
..... 24.38.1 Library
.... 24.39 Recommendation #10 - Urine Drug Testing (order-sign)
..... 24.39.1 Library
.... 24.40 Recommendation #10 - Urine Drug Testing (order-sign)
..... 24.40.1 Library
.... 24.41 Recommendation #10 - Urine Drug Testing (order-sign)
..... 24.41.1 Library
.... 24.42 Recommendation #10 - Urine Drug Testing (patient-view)
..... 24.42.1 Library
.... 24.43 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines (order-select)
..... 24.43.1 Library
.... 24.44 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines (patient-view)
..... 24.44.1 Library
.... 24.45 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder (patient-view)
..... 24.45.1 Library
.... 24.46 Morphine Milligram Equivalent (MME) Conversion Factors for FHIR R4
.... 24.47 Morphine Milligram Equivalent (MME) Calculator for FHIR R4
.... 24.48 Opioid Management Terminology Knowledge Data
.... 24.49 Opioid Management Terminology Knowledge Logic
.... 24.50 Module Configuration Library for Recommendation 10 (EPIC prefetch configuration)
.... 24.51 OpioidCDSREC10OrderSelect
.... 24.52 OpioidCDSREC10OrderSignCRD
.... 24.53 CDC_CarePlan
.... 24.54 CDC_MedicationRequest
.... 24.55 CDC_Observation
.... 24.56 CDC_RequestGroup
.... 24.57 CDC_ValueSet
.... 24.58 DataDateRollerExtension
.... 24.59 EffectiveDataRequirement Extension
.... 24.60 CDC 2022 Opioid Guidance Clinical Focus Extension
.... 24.61 CDC 2022 Opioid Guidance Data Element Extension
.... 24.62 CDC 2022 Opioid Guidance exclusion Criteria Extension
.... 24.63 CDC 2022 Opioid Guidance Inclusion Criteria Extension
.... 24.64 Barbiturate urine drug screening tests
.... 24.65 Benzodiazepine urine drug screening tests
.... 24.66 Buprenorphine urine drug screening tests
.... 24.67 Heroin urine drug screening tests
.... 24.68 Oxycodone urine drug screening tests
.... 24.69 ValueSet - Medication Request Category Community
.... 24.70 ValueSet - Medication Request Status Active
.... 24.71 CodeSystem - CDC 2022 Opioid Indicator
.... 24.72 CDC_Opioid_Override_Reasons
.... 24.73 OpioidCDS CarePlan
.... 24.74 Cancer Diagnosis Condition
.... 24.75 End of Life Condition
.... 24.76 Terminal Condition
.... 24.77 Cancer Diagnosis Encounter
.... 24.78 Oncology Participant Encounter
.... 24.79 Ambulatory Opioid MedicationDispense
.... 24.80 OpioidCDS MedicationRequest
.... 24.81 Ambulatory Opioid MedicationRequest
.... 24.82 OpioidCDS Observation
.... 24.83 OpioidCDS Patient
.... 24.84 Oncology Specialist PractitionerRole
.... 24.85 OpioidCDS RequestGroup
.... 24.86 Palliative Care ServiceRequest
.... 24.87 Ethanol urine drug screening tests
.... 24.88 All urine drug screening tests
.... 24.89 Amphetamine-class drugs and metabolite urine tests
.... 24.90 Amphetamine class medications
.... 24.91 Barbiturate Medications
.... 24.92 Benzodiazepine medications
.... 24.93 Buprenorphine and Methadone medications
.... 24.94 Buprenorphine Medications
.... 24.95 Cannabinoid class urine drug screening
.... 24.96 CDC malignant cancer conditions
.... 24.97 CNS depressant medications
.... 24.98 Cocaine urine drug screening tests
.... 24.99 Sleep disordered breathing
.... 24.100 Conditions documenting substance misuse
.... 24.101 Conditions likely terminal for opioid prescribing
.... 24.102 Extended release opioid with ambulatory misuse potential
.... 24.103 Fentanyl-type medications
.... 24.104 Fentanyl-type urine drug screening tests
.... 24.105 General opiate urine drug screening tests
.... 24.106 Hospice Finding
.... 24.107 Hospice Procedure
.... 24.108 Limited life expectancy conditions
.... 24.109 Methadone urine drug screening tests
.... 24.110 Methadone medications
.... 24.111 Naloxone medications
.... 24.112 Ambulatory setting non-opioid CNS depressant medications
.... 24.113 Non-opioid drug urine screening
.... 24.114 Non-synthetic opioid medications
.... 24.115 Oncology specialty designations (NUCC)
.... 24.116 Opiate medications
.... 24.117 Opiate specific urine drug screening tests
.... 24.118 Opioid analgesics with ambulatory misuse potential
.... 24.119 Opioid counseling procedure
.... 24.120 Opioid drug urine screening
.... 24.121 Opioid misuse assessment procedure
.... 24.122 Opioid misuse disorders
.... 24.123 Opioid treatment assessment procedure
.... 24.124 Oxycodone Medications
.... 24.125 Pain management procedure
.... 24.126 Pain treatment plan
.... 24.127 PDMP data reviewed finding
.... 24.128 PDMP review procedure
.... 24.129 Phencyclidine urine drug screening tests
.... 24.130 Sickle-cell diseases
.... 24.131 Substance misuse behavioral counseling
.... 24.132 Synthetic opioid medications
.... 24.133 Synthetic opioid urine drug screening tests
.... 24.134 Therapies indicating end of life care
.... 24.135 Condition Clinical Status Active
.... 24.136 Encounter Diagnosis Condition Category
.... 24.137 Problem List Condition Category
.... 24.138 US Core Health Concern Condition Category
.... 24.139 Hospice Disposition
.... 24.140 Observation Category Laboratory
.... 24.141 Observation Category Procedure
.... 24.142 Office Visit
.... 24.143 CQFToolingDevice